ImmuPharma (LON:IMM) Stock Price Up 9.5% - Time to Buy?

Key Points

• ImmuPharma plc shares increased by 9.5% during mid-day trading, reaching a high of GBX 14.20 ($0.19).
• The company has a market capitalization of £60.47 million and reported a negative earnings per share of GBX (0.38) for the last quarter.
• ImmuPharma focuses on peptide-based therapeutics for autoimmune diseases, with its lead program, P140 (Lupuzor™), targeting the treatment of Lupus.

Shares of ImmuPharma plc (LON:IMM - Get Free Report) shot up 9.5% during mid-day trading on Tuesday . The stock traded as high as GBX 14.20 ($0.19) and last traded at GBX 12.10 ($0.16). 23,646,498 shares changed hands during mid-day trading, an increase of 176% from the average session volume of 8,583,096 shares. The stock had previously closed at GBX 11.05 ($0.15).

ImmuPharma Stock Performance

The stock has a fifty day simple moving average of GBX 4.46 and a two-hundred day simple moving average of GBX 3.33. The stock has a market capitalization of £60.47 million, a price-to-earnings ratio of -1,359.55 and a beta of 1.53.

ImmuPharma (LON:IMM - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. Research analysts forecast that ImmuPharma plc will post -339.0000022 earnings per share for the current year.

ImmuPharma Company Profile

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.